Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX
Rice Hall James & Associates LLC recently acquired 93,396 shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, valued at approximately $2.37 million, representing about 0.23% of the company. Other institutional investors have also adjusted their holdings, while company insiders have sold shares. Pacira BioSciences reported strong earnings, beating analyst estimates, and has received a consensus "Hold" rating from Wall Street analysts with an average target price of $30.20.
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock
Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to $24.00, and it recently beat EPS estimates with a revenue increase of 6.2% year-over-year.
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan
Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, Slonin directly holds 216,383.646 shares, which includes shares acquired via the company’s employee stock purchase plan.
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026
Pacira BioSciences (NASDAQ: PCRX) is set to see a proposed sale of 3,040 common shares with an aggregate market value of $70,619.20 on August 17, 2026. The sale, detailed in a Form 144 SEC filing, will be executed through Fidelity Brokerage Services LLC on the NASDAQ market. The shares were originally acquired by the filer through an Employee Stock Purchase Plan and restricted stock vesting in mid-2022.
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial
Truist Financial initiated coverage on Pacira BioSciences (NASDAQ:PCRX) with a "buy" rating and a $30.00 price target, suggesting a 28.81% potential upside. This comes after Pacira BioSciences reported strong quarterly earnings, exceeding analyst estimates with $0.73 EPS and $192.4 million in revenue, a 6.2% increase year-over-year. Despite these positive developments and institutional investor interest, the company maintains a "Hold" consensus rating among analysts, with an average price target of $30.20.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages
Brokerages have issued a consensus "Hold" rating for Pacira BioSciences (NASDAQ:PCRX), with an average 12-month price target of $29.80 against its current price of $23.00. The company recently surpassed quarterly earnings estimates, reporting $0.73 EPS on $192.4 million in revenue. Institutional investors hold a significant 99.73% of the shares, while an insider recently sold a portion of their holdings.
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact
Pacira Biosciences (NASDAQ:PCRX) is presented as a compelling value investment due to its strong valuation metrics, including low P/E and Price/Free Cash Flow ratios, despite a mixed but acceptable financial health and profitability profile. While growth has been a weaker point historically, analyst expectations for future EPS growth, combined with its strong free cash flow generation, suggest it may be an undervalued opportunity. Investors are cautioned to consider risks such as declining margins and a leveraged balance sheet.
Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX
Empowered Funds LLC significantly increased its stake in Pacira BioSciences (NASDAQ:PCRX) by 21.6% in the first quarter, acquiring 49,171 additional shares, bringing its total holding to 276,776 shares valued at $6.3 million. This increase contributes to institutional investors owning 99.73% of the company's stock. The news follows Pacira's strong Q1 earnings, where it surpassed analyst estimates with $0.73 EPS and a 6.2% year-over-year revenue increase, despite mixed analyst ratings and a recent insider stock sale.
Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX
Wedge Capital Management L L P NC has acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX), purchasing 94,554 shares valued at approximately $2.4 million. This acquisition makes Wedge Capital a 0.24% owner of the company, which reports 99.73% institutional ownership. Pacira BioSciences recently exceeded quarterly EPS estimates and saw a 6.2% increase in revenue year-over-year, despite analysts maintaining a consensus "Hold" rating with a price target of $29.80.
Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX
Assenagon Asset Management S.A. recently acquired 101,429 shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) valued at approximately $2.57 million, increasing institutional ownership to 99.73%. Despite a consensus "Hold" rating from analysts, the company exceeded Q2 expectations with $0.73 EPS and $192.4 million in revenue, an increase of 6.2% year-over-year. Insider activity shows SVP Lauren Riker selling 6,115 shares for $143,702.50 in June.
(PCRX) and the Role of Price-Sensitive Allocations
This article analyzes Pacira Biosciences Inc
Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data
Pacira BioSciences' stock (PCRX) fell 7.1% despite advancing its PCRX-201 gene therapy for knee osteoarthritis into Phase 2 following positive two-year Phase 1 data. The company also announced revised full-year revenue expectations of US$735 million to US$760 million, down from prior guidance, but reported a swing to profitability in Q2. Investors are weighing the long-term potential of the gene therapy pipeline against near-term financial pressures and execution risks.
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX
Hennion & Walsh Asset Management Inc. increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 31% in the second quarter, purchasing an additional 48,124 shares to now own 203,520 shares valued at approximately $5.16 million. Pacira recently reported strong quarterly earnings of $0.73 per share, surpassing consensus estimates, with revenue rising 6.2% year-over-year to $192.4 million. Analyst sentiment is mixed, with an overall "Hold" rating and an average price target of $29.80, though some analysts have raised their targets.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement awards granted to five new employees on August 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, approved by the People & Compensation Committee without stockholder approval in accordance with Nasdaq Listing Rule 5635(c)(4), include stock options for 8,500 shares and restricted stock units for 14,200 shares of Pacira common stock. The grants serve as a material inducement for their employment with the company.
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen has upgraded Pacira BioSciences (NASDAQ:PCRX) to a "strong-buy" rating from "buy," despite the broader analyst consensus remaining "Hold" with an average price target of $29.80. The company reported strong quarterly earnings, beating analyst estimates with EPS of $0.73 and revenue of $192.4 million, a 6.2% increase year-over-year. Institutional investors hold a significant 99.73% of the company's shares.
Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement grants of stock options and restricted stock units (RSUs) to seven new employees. These grants, totaling 19,850 stock options and 11,000 RSUs, were made outside the company's existing equity incentive plans as an inducement material to the new hires' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over four years, subject to continued employment.
State Street Corporation (NYSE: STT) discloses 5.2% ownership in Pacira BioSciences
State Street Corporation has disclosed a beneficial ownership of 2,059,977 shares, or 5.2%, of Pacira BioSciences Inc. common stock, as detailed in a Schedule 13G SEC filing. This filing indicates that State Street, along with its investment adviser subsidiaries, holds shared voting power over 1,944,697 shares and shared dispositive power over all 2,059,977 shares. The ownership is primarily for investment purposes, with no sole voting or dispositive power reported, meaning control is exercised jointly through entities like SSGA Funds Management, Inc. and various State Street Global Advisors affiliates.
Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results
This article examines the latest analyst forecasts for Pacira BioSciences, Inc. (NASDAQ:PCRX) following its second-quarter results. It provides an overview of the consensus earnings estimates and how they have changed over time, along with an assessment of the company's financial performance and future prospects according to market analysts. Investors can gain insights into the potential trajectory of PCRX based on these expert opinions.
Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc.
Pacer Advisors Inc. increased its stake in Pacira BioSciences, Inc. by 24.5% in the first quarter, now owning 235,427 shares. The company reported strong Q2 revenue and EPS, exceeding analyst expectations, but its 2026 revenue guidance fell below consensus. Analyst sentiment is mixed, with some raising price targets and others maintaining a more cautious outlook, resulting in an overall "Hold" rating for the stock.
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Pacira BioSciences announced the publication of positive two-year results from its Phase 1 clinical trial for PCRX-201, an investigational gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The study found that a single intra-articular injection of PCRX-201 was well-tolerated and showed improvements in pain, stiffness, and function for up to two years. The company is advancing PCRX-201 into its Phase 2 ASCEND trial, with initial topline data expected by year-end 2026.
Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside
Pacira BioSciences, Inc.'s stock price target has been raised to $30 from $29.67 by 6 analysts, suggesting a 9% potential upside from its August 4 closing price. The consensus rating for PCRX remains a "Buy," with a breakdown of 3 Buys, 2 Holds, and 1 Sell among the analysts. Investors can explore more data and track recommendations on TradingView's platform.
Pacira BioSciences (NASDAQ: PCRX) earns Q2 profit and sells iovera business
Pacira BioSciences (NASDAQ: PCRX) reported a profit in Q2 2026 with total revenues of $192.4 million, driven by strong sales of EXPAREL and ZILRETTA. The company also announced the divestiture of its iovera° cryoanalgesia business to Zimmer for up to $140 million, including an upfront payment of $70 million. This strategic move aligns with Pacira's focus on innovative biopharmaceutical products and is expected to enhance its financial position, despite a decrease in interest income and a slight increase in operating expenses.
Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test
Pacira BioSciences (PCRX) has advanced its osteoarthritis gene therapy candidate, PCRX-201, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. The company's shares are currently trading at US$26.92, which is significantly below its narrative fair value of $38.00, suggesting it is undervalued. Despite a 52.07% decline in total shareholder return over five years, the past year has shown improving momentum with a 19.43% return.
Pacira BioSciences Q2 Earnings Call Highlights
Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer Biomet. Pacira updated its full-year revenue guidance to reflect the divestiture but maintained its EXPAREL sales outlook, emphasizing growth from outpatient settings and commercial reimbursement.
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Pacira BioSciences (PCRX) reported strong second-quarter 2026 results, beating analyst estimates for both earnings and revenues, driven by demand for Exparel, Zilretta, and iovera. Despite the strong performance, the company cut its 2026 sales outlook due to the divestiture of iovera, while maintaining other financial guidance. Pacira also secured a major win with UnitedHealthcare providing separate reimbursement for Exparel, expanding its covered lives.
RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating
RBC has increased its price target for Pacira Biosciences (PCRX) to $25 from $24, while maintaining a Sector Perform rating on the stock. This adjustment comes shortly after Pacira BioSciences reported its Q2 2026 earnings, posting an adjusted EPS of $0.73 per share against an estimated $0.65, and revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million. The company also updated its earnings guidance for the full year 2026.
Pacira BioSciences Q2 2026 Earnings Call Transcript
Pacira BioSciences reported its Q2 2026 earnings, highlighting a 6% increase in total revenue to $192.4 million, driven by EXPAREL, ZILRETTA, and iovera° sales growth. The company successfully divested iovera° to Zimmer Biomet and lowered its full-year 2026 revenue guidance to $735 million-$760 million. Pacira emphasized strategic partnerships, pipeline advancements, and expanded commercial payer coverage for EXPAREL, including UnitedHealthcare, as key drivers for future growth despite a slowdown in certain elective soft tissue procedures.
Pacira Q2 2026 earnings: Revenue rises as adjusted EBITDA declines
Pacira BioSciences reported a 6% revenue increase to $192.4 million in Q2 2026, yet adjusted EBITDA declined by approximately 10% and non-GAAP net income fell 18% due to rising expenses. The company also lowered its full-year revenue guidance following the divestiture of iovera°. Despite a GAAP net income improvement, underlying operating profitability weakened, with EXPAREL remaining the primary revenue driver.
Pacira BioSciences, Inc. 2026: Revenue $192.4M, EPS $0.12— 10-Q Summary
Pacira BioSciences, Inc. reported strong financial results for the 2026 quarter, with revenue of $192.4M and diluted EPS of $0.12, showing significant growth compared to the prior year. Key drivers included increased net product sales for EXPAREL and ZILRETTA, expanded reimbursement for EXPAREL, and the divestiture of iovera° to Zimmer. The company also advanced its clinical pipeline and addressed potential risks related to supply chain and tariffs.
Pacira BioSciences Q2 Earnings Call Highlights
Pacira BioSciences (NASDAQ:PCRX) reported a 6% increase in second-quarter revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company completed the sale of iovera° to Zimmer Biomet for up to $140 million and updated its full-year revenue guidance to $735 million-$760 million. Pacira anticipates three key clinical readouts by year-end, focusing on its non-opioid pain management pipeline.
Pacira BioSciences Q2 revenue rises 6% to $192.4 million
Pacira BioSciences reported a 6% increase in Q2 2026 revenue, reaching $192.4 million, with GAAP net income of $4.7 million. The company completed the divestiture of its iovera° business and updated its full-year revenue guidance to $735 million to $760 million. Insider trading activity showed sales by officers, while institutional investors had mixed movements in their holdings.
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q2 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.65
Pacira BioSciences, Inc. (PCRX) announced its Q2 adjusted EPS was $0.73 per share, surpassing the FactSet estimate of $0.65. The company also reported Q2 revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million, and provided updated earnings guidance for the full year 2026. Additionally, RBC adjusted its price target for Pacira BioSciences to $25 from $24, maintaining a Sector Perform Rating.
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Pacira BioSciences reported solid financial results for the second quarter of 2026, with total revenue reaching $192.4 million, a 6% year-over-year increase. The company highlighted progress on its 5x30 strategy, including the divestiture of its iovera® business, expanded reimbursement for EXPAREL® by UnitedHealthcare, and advancement of its PCRX-201 development program. Pacira also updated its full-year 2026 financial guidance to reflect the iovera® divestiture.
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Pacira BioSciences released findings from its "Standing Strong: The Impact of Pain on America's Workforce" survey, highlighting that 85% of workers in physically demanding jobs experience pain while working, with chronic knee pain being a prevalent issue. The survey revealed significant impacts on income, career advancement, and quality of life, alongside a strong interest in long-lasting, non-opioid pain management options among those with chronic knee pain, even though 24% currently use prescription opioids. The company emphasized the need to raise awareness about effective non-opioid alternatives to help workers manage pain and improve their quality of life.
Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Pacira Biosciences Inc (PCRX), detailing its current risk score, beta value, and various volatility metrics. The company ranks 49th out of 155 in the pharmaceuticals industry with a risk assessment score of 6.68 and a beta of 0.30, indicating lower volatility compared to the S&P 500. The report also includes data on maximum drawdown, Sharpe Ratio, and liquidity.
Pacira BioSciences Advances PCRX-201 Development Program
Pacira BioSciences announced the successful transition of its PCRX-201 gene therapy for osteoarthritis of the knee to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. This development supports the company's 5x30 growth strategy and advances a key pipeline program. Topline data from Part A of the ASCEND study is still expected by the end of 2026.
Pacira enrolls first patient in Phase 2 ASCEND Part B trial of knee osteoarthritis gene therapy PCRX-201
Pacira Biosciences has enrolled the first patient in Part B of its Phase 2 ASCEND trial for PCRX-201, an investigational gene therapy for knee osteoarthritis. This milestone follows the transition to a U.S.-based commercial-scale manufacturing process. Topline results for Part A of the study, which completed enrollment in June, are anticipated by the end of 2026.
Pacira's knee gene therapy gets new-process drug for Phase 2
Pacira BioSciences has successfully transitioned its investigational gene therapy PCRX-201 for osteoarthritis of the knee to a scalable U.S.-based commercial manufacturing process. This allowed the enrollment of the first patient in Part B of the Phase 2 ASCEND study, while Part A enrollment concluded in June with topline data expected by the end of 2026. The company emphasizes that this manufacturing change did not delay the trial and validates its high-capacity adenovirus platform, supporting the program's progression towards potential commercialization.
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Pacira BioSciences has successfully transitioned its PCRX-201 (enekinragene inzadenovec) gene therapy for knee osteoarthritis to a scalable commercial manufacturing process, enabling the first patient enrollment in Part B of the Phase 2 ASCEND study. This advancement supports the company's growth strategy and de-risks future development by using a manufacturing process intended for late-stage development and commercialization. Topline data for Part A of the ASCEND study is still expected by the end of 2026.
Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone
Pacira BioSciences has enrolled its first patient in a mid-stage clinical trial for PCRX-201, a gene therapy aimed at treating osteoarthritis. This milestone follows the successful transition of PCRX-201 to a scalable commercial manufacturing process, underscoring the company's progress in advancing its non-opioid pain management and therapeutic pipeline. The company also recently announced that UnitedHealthcare will provide separate reimbursement for EXPAREL, another key product.
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Pacira BioSciences announced the successful transition of its investigational gene therapy, PCRX-201, to a scalable commercial manufacturing process, enabling the enrollment of the first patient in Part B of the Phase 2 ASCEND study. This milestone supports the company's "5x30 growth strategy" and reduces development risk by using a manufacturing process intended for later-stage development and commercialization. Topline data from Part A of the ASCEND study is expected by the end of 2026.
Pacira Biosciences Inc (PCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pacira Biosciences Inc (PCRX) focusing on its dividends and stock splits. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and P/E ratio are also presented.
Pacira Biosciences Inc (PCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Pacira Biosciences Inc (PCRX), categorizing its revenue by business segments for the fiscal year 2025. It shows that EXPAREL contributes the largest proportion of revenue, followed by ZILRETTA, iovera, and Bupivacaine liposome injectable suspension. The report indicates that regional revenue data has not yet been disclosed by the company.
Pacira Biosciences Inc (PCRX) Cash Flow
This article provides a detailed cash flow statement for Pacira Biosciences Inc (PCRX), covering quarterly and annual data for various cash flow components from operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures for numerous periods. The document also features FAQs defining key cash flow terms and their relevance to PCRX's financial health.
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after the U.S. markets close on Tuesday, August 4, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results, with registration available for Q&A participation. A replay of the webcast will also be accessible on the Pacira website for two weeks following the call.
Pacira Biosciences, Inc. Revenue Breakdown – FWB:82P
Pacira Biosciences, Inc. (FWB:82P) generated €618.48 million in revenue last year, primarily from its Non-opioid Pain Management and Regenerative Health Solutions segment. This revenue largely came from the United States, European Union, United Kingdom, and Canada, though it represents a decrease from the previous year's €677.12 million. The article provides a breakdown of the company's top-performing segments and regional contributions.
Pacira BioSciences, Inc. (PCRX) stock price, news, quote and history
This article provides comprehensive financial information for Pacira BioSciences, Inc. (PCRX), including its current stock price, historical data, key financial metrics, and analyst ratings. It details the company's focus on non-opioid pain management solutions and regenerative health, outlining its flagship products like EXPAREL and ZILRETTA, and its pipeline projects. The report also offers performance comparisons against the S&P 500 and lists similar companies in the specialty and generic drug manufacturing industry.
Pacira Biosciences Inc (PCRX) Institutional Confidence
Pacira Biosciences Inc (PCRX) shows an institutional confidence score of 10.00, ranking first in the Pharmaceuticals industry. Institutional shareholding stands at 122.53%, indicating a 1.68% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 4.64% of the shares outstanding.
Pacira Biosciences Inc (PCRX) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Pacira Biosciences Inc (PCRX), highlighting its current valuation score of 8.28, which ranks 102 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is 205.94, which is below its recent high and above its recent low. However, data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pacira stock trades steady as EXPAREL revenue supports margins
Pacira BioSciences (PCRX) stock is trading steadily due to strong EXPAREL revenue and resilient margins, balancing moderate growth with efficient operations. The company, focused on non-opioid pain management, reported $180 million in quarterly revenue and over $700 million annually in fiscal 2024, with EXPAREL sales driving a 5% year-over-year revenue increase. Pacira emphasizes expanding non-opioid solutions in surgical settings and maintaining a gross margin above 70%, reflecting its stable position in the US pharmaceuticals sector despite competitive pressures.
